Call Us Now

+91 9606900005 / 04

For Enquiry

legacyiasacademy@gmail.com

PHASE-1 TRIAL: ADENOVIRUS COVID-19 VACCINE FOUND SAFE

Why in news?

A phase-1 trial using a single dose of a vaccine (Ad5-nCoV) that uses a recombinant adenovirus type-5 vector that carries the genetic material that codes for spike glycoprotein of novel coronavirus was found to be safe, well-tolerated and able to generate immune responses against the virus.

Details

  • The adenovirus is a weakened common cold virus.
  • It was the first-in-human study of the adenovirus type-5 vectored COVID-19 vaccine.
  • The vaccine was found to elicit neutralising antibodies, which peaked at day 28 post-vaccination, while rapid specific T-cell responses peaked at day 14 after vaccination.
  • The antibody response to the vaccine in the high-dose group was slightly greater than that in the middle-dose and low-dose groups.

Click Here to read more about Human trials and the phases

-Source: The Hindu

Download PDF
October 2022
MTWTFSS
 12
3456789
10111213141516
17181920212223
24252627282930
31 
Categories